

Published in final edited form as:

*J Med Genet.* 2012 March ; 49(3): 187–191. doi:10.1136/jmedgenet-2011-100394.

## Haploinsufficiency of *COQ4* causes coenzyme Q<sub>10</sub> deficiency

Leonardo Salviati<sup>1</sup>, Eva Trevisson<sup>1</sup>, Maria Angeles Rodriguez Hernandez<sup>2</sup>, Alberto Casarin<sup>1</sup>, Vanessa Pertegato<sup>1</sup>, Mara Doimo<sup>1</sup>, Matteo Cassina<sup>1</sup>, Caterina Agosto<sup>3</sup>, Maria Andrea Desbats<sup>1</sup>, Geppo Sartori<sup>4</sup>, Sabrina Sacconi<sup>5</sup>, Luigi Memo<sup>6</sup>, Orsetta Zuffardi<sup>7</sup>, Rafael Artuch<sup>8</sup>, Catarina Quinzii<sup>9</sup>, Salvatore DiMauro<sup>9</sup>, Michio Hirano<sup>9</sup>, Carlos Santos-Ocaña<sup>2</sup>, and Plácido Navas<sup>2</sup>

<sup>1</sup>Clinical Genetics Unit, Department of Pediatrics, University of Padova, Padova, Italy

<sup>2</sup>Centro Andaluz de Biología del Desarrollo, and CIBERER, Instituto de Salud Carlos III, Universidad Pablo de Olavide-CSIC, Sevilla, Spain

<sup>3</sup>Department of Pediatrics, University of Padova, Padova, Italy

<sup>4</sup>Department of Biochemistry, University of Padova, Padova, Italy

<sup>5</sup>Centre de référence des maladies Neuromusculaires, Nice Hospital and UMR CNRS6543, Nice University, Nice, France

<sup>6</sup>Pediatrics and Neonatology Unit, San Martino Hospital, Belluno, Italy

<sup>7</sup>Department of Biology and Medical Genetics, University of Pavia, and Fondazione IRCCS C. Mondino, Pavia, Italy

<sup>8</sup>Department of Clinical Biochemistry, Hospital Sant Joan de Déu and Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III. Barcelona, Spain

<sup>9</sup>Department of Neurology, Columbia University Medical Center, New York, New York, USA

### Abstract

**Background**—*COQ4* encodes a protein that organises the multienzyme complex for the synthesis of coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>). A 3.9 Mb deletion of chromosome 9q34.13 was identified in a 3-year-old boy with mental retardation, encephalomyopathy and dysmorphic features. Because the deletion encompassed *COQ4*, the patient was screened for CoQ<sub>10</sub> deficiency.

**Methods**—A complete molecular and biochemical characterisation of the patient's fibroblasts and of a yeast model were performed.

**Results**—The study found reduced *COQ4* expression (48% of controls), CoQ<sub>10</sub> content and biosynthetic rate (44% and 43% of controls), and activities of respiratory chain complex II+III. Cells displayed a growth defect that was corrected by the addition of CoQ<sub>10</sub> to the culture medium. Knockdown of *COQ4* in HeLa cells also resulted in a reduction of CoQ<sub>10</sub>. Diploid yeast

Correspondence to Leonardo Salviati, Clinical Genetics Unit, Department of Pediatrics, University of Padova, Via Giustiniani 3, 35128 Padova, Italy; leonardo.salviati@unipd.it.

**Competing interests** None.

**Patient consent** All analyses were performed with the informed consent of the parents of the patients. All analyses on patient fibroblasts were part of the standard set of investigations carried out to diagnose coenzyme Q deficiency.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Contributors** LS: study design, acquisition of data, drafting manuscript, provided funding. ET: study design, acquisition of data, drafting manuscript. MARH: acquisition of data, drafting manuscript. AC, VP, MD, CA, MAD, SS, LM, CQ, CSO and PN: acquisition of data, revising manuscript. MC and RA: study design, revising manuscript. GS, OZ, SDM and MH: acquisition of data, revising manuscript, provided funding. The first two authors contributed equally to this work.

haploinsufficient for *COQ4* displayed similar CoQ deficiency. Haploinsufficiency of other genes involved in CoQ<sub>10</sub> biosynthesis does not cause CoQ deficiency, underscoring the critical role of *COQ4*. Oral CoQ<sub>10</sub> supplementation resulted in a significant improvement of neuromuscular symptoms, which reappeared after supplementation was temporarily discontinued.

**Conclusion**—Mutations of *COQ4* should be searched for in patients with CoQ<sub>10</sub> deficiency and encephalomyopathy; patients with genomic rearrangements involving *COQ4* should be screened for CoQ<sub>10</sub> deficiency, as they could benefit from supplementation.

Coenzyme Q (CoQ) is a vital molecule that transports electrons from mitochondrial respiratory chain (RC) complexes I and II to complex III. CoQ comprises a quinone group and a polyisoprene tail of varying length in different species, six in yeast (CoQ<sub>6</sub>) and 10 in humans (CoQ<sub>10</sub>). More than 10 nuclear genes (*COQ* genes) are involved in its biosynthetic pathway in yeast, for which there are homologous genes in virtually all eukaryotic species.<sup>1</sup>

In yeast, *COQ* gene products form a multienzyme complex organised around Coq4p,<sup>2</sup> which does not appear to possess a specific enzymatic activity but plays rather a structural role. Human *COQ4*, on chromosome 9q34.13, encodes a ubiquitously expressed mitochondrial protein, which is able to complement the corresponding yeast deletion mutant functionally.<sup>3</sup>

Defects of *COQ* genes cause primary CoQ<sub>10</sub> deficiency, a clinically and genetically heterogeneous group of disorders, presenting as isolated nephrotic syndrome, as a multisystemic infantile disease, or as juvenile-onset ataxia, which are usually inherited as autosomal recessive traits.<sup>1</sup> We now report a patient with CoQ<sub>10</sub> deficiency associated with haploinsufficiency of *COQ4*.

## PATIENTS AND METHODS

### Case report

PT1 was born to healthy, non-consanguineous parents after an uneventful pregnancy. Weight, body length and head circumference were at the third percentile. He had dysmorphic features (epicanthal folds, broad nose, coarse facial features, syndactyly), a small ventricular septal defect, weakness, hypotonia and hyporeactivity. A standard karyotype performed at birth was normal. Tetrasomy 12p was suspected but was ruled out by karyotyping cultured skin fibroblasts. In subsequent months, growth was poor, hypotonia and weakness worsened and he had recurrent severe respiratory infections, which required hospitalisation. Serum lactic acid, ammonia and creatine kinase were normal. He did not have proteinuria and urinary organic acids were also normal. Because of the severe hypotonia a congenital myopathy was suspected and he underwent a muscle biopsy at another institution, which showed only increased subsarcolemmal succinate dehydrogenase staining in some fibres, and a prevalence of type I fibres, but no ragged-red fibres.

He was seen in our clinic at age 3 years. He had moderate mental retardation, was still unable to walk and did not speak. He was severely hypotonic and weak but had no other focal neurological deficit.

All studies have been performed with the informed consent of the parents. Skin fibroblasts had been obtained previously for the diagnosis of tetrasomy 12p syndrome.

PT2 and PT3 are the healthy parents of the previously reported child with CoQ<sub>10</sub> deficiency caused by mutations in *PDSS2*.<sup>4</sup>

## METHODS

Array comparative genomic hybridisation analysis was performed using the Agilent 4×44K chip (Agilent, Santa Clara, CA, USA) according to the manufacturer's protocol. *COQ4* sequencing, and real-time quantitative (RQ)-PCR analysis have been reported previously.<sup>3</sup>

Measurements of respiratory chain enzyme activities,<sup>5</sup> CoQ<sub>10</sub> levels,<sup>4</sup> incorporation of radiolabelled para-hydroxybenzoate<sup>6</sup> and fibroblast growth assays were performed as described.

Stable knockdown of *COQ4* was performed in HeLa cells using specific small hairpin RNA expression vectors (HuSH pGFP-V-RS) purchased from OriGene (OriGene, Rockville, MD, USA) (shRNA sequences are available upon request). The vector contains a puromycin resistance gene and green fluorescent protein (GFP). After transfection cells were selected for puromycin resistance and by flow cytometry sorting GFP-positive cells.

*COQ4* plasmid vectors and CoQ<sub>6</sub> determination procedures have been described previously.<sup>3,67</sup> Heterozygous strains for *COQ4*, *COQ2* or *COQ6* deletions were obtained by mating mat *a* haploid BY4741 deletion mutants, with mat  $\alpha$  wild-type BY4742 cells. The mating and transformation procedures were performed as described.<sup>8</sup> All biochemical analyses were performed after growth in non-fermentable medium containing glycerol (YPG).

## RESULTS

### Genetic studies

The presence of developmental delay and dysmorphic features was suggestive of a genomic alteration and array comparative genomic hybridisation detected a de-novo 3.9 Mb deletion of chromosome 9q34 (figure 1A,B) in DNA extracted from blood leucocytes. The deletion encompassed the *COQ4* gene and its presence was confirmed in cultured skin fibroblasts by RQ-PCR analysis (figure 1C), but spares the *STXBPI* gene. The supplementary table (available online only) lists all the genes included in the deleted region. *COQ4* messenger RNA expression was reduced in these cells (48% of controls) (figure 2A), consistent with monoallelic expression. We ruled out the presence of a second mutation in the residual *COQ4* allele by direct sequencing of both genomic DNA and complementary DNA.

### Biochemical analyses

Combined activity of complex II+III was reduced in fibroblasts (figure 2B), contrasting with normal activities of other enzymes, especially complex II and complex III and citrate synthase. These findings suggested CoQ<sub>10</sub> deficiency. In fact, both steady-state levels of CoQ<sub>10</sub> (43%) (figure 2C) and its biosynthetic rate measured by para-hydroxybenzoate incorporation (44%) (figure 2D) were decreased in the patient's fibroblasts.

### Heterozygosity for *PDSS2* mutations does not cause CoQ deficiency

We analysed CoQ<sub>10</sub> levels in fibroblasts obtained from PT2 and PT3, the parents of a patient with *PDSS2* mutations (N322X/S382L)<sup>4</sup> who were both heterozygous carriers. In both cell lines, CoQ<sub>10</sub> levels were normal (figure 2C), whereas the patient had CoQ<sub>10</sub> levels less than 10% of controls.<sup>4</sup>

### CoQ<sub>10</sub> supplementation restores growth in patient's cells

Fibroblasts of PT1 displayed reduced growth compared with control cells, while supplementation with 10  $\mu$ M CoQ<sub>10</sub> restored a normal growth pattern (figure 2E) and complex II+III enzymatic activity in these cells (figure 2F).

### Knockdown of *COQ4* causes CoQ<sub>10</sub> deficiency in HeLa cells

We generated HeLa cells stably transfected with a specific *COQ4* shRNA vector. Analysis of two different clones showed a direct relationship between *COQ4* mRNA expression levels (figure 2G) and CoQ<sub>10</sub> content (figure 2H). In particular, clone 2 had approximately 50% residual *COQ4* mRNA and 54% CoQ<sub>10</sub>, a situation that closely resembles that of the patient's cells.

### Haploinsufficiency of *COQ4* causes CoQ deficiency in yeast

Because *COQ4* is highly conserved and the human gene effectively complements yeast *COQ4<sup>null</sup>* strains,<sup>3</sup> we used *Saccharomyces cerevisiae* as a model to study the effects of *COQ4* haploinsufficiency. Diploid yeast carrying a deletion of one *COQ4* allele displayed a reduction of CoQ content relative to the wild-type strain, which was comparable to that observed in our patient's cells (figure 2I). Moreover, they displayed a similar reduction of the activity of complex II+III, 59 $\pm$ 2% of the wildtype strain. Transformation with wild-type *COQ4* rescued CoQ deficiency in these cells. We could not detect any defect in diploid yeast strains harbouring heterozygous deletions of *COQ2* or *COQ6* (figure 2J).

### Effect of CoQ<sub>10</sub> supplementation in the patient

After documenting CoQ<sub>10</sub> deficiency in the patient, we started him on oral CoQ<sub>10</sub> supplementation (30 mg/kg per day of ubiquinone). There was a clear improvement in muscle tone and strength, which became evident after 3 weeks of therapy. The patient began to walk unassisted after 5 weeks. The parents reported a general improvement not only in physical endurance, but also in his attention and social interaction. He also began to speak a few words. The improvement has been stable for 3 years; during this period he did not present with any severe respiratory infection. Interestingly, when the formulation was changed from phials to soft-gel capsules, the dosage was inadvertently reduced to 2 mg/kg per day of ubiquinone. After approximately 2 weeks the patient developed weakness and complained of diffuse myalgias. The dosage was immediately increased to 30 mg/kg per day of ubiquinone, with remission of symptoms within a week. Treatment was then switched to ubiquinol, the reduced form of CoQ, with a daily dosage of 15 mg/kg per day, without any significant problems.

## DISCUSSION

Primary CoQ<sub>10</sub> deficiency is unique among mitochondrial disorders because early supplementation with CoQ<sub>10</sub> can prevent the onset of neurological and renal manifestations.<sup>9</sup> It is therefore of crucial importance to identify CoQ<sub>10</sub>-deficient patients and to characterise them at the molecular level.

While primary CoQ<sub>10</sub> deficiency is usually inherited as an autosomal recessive disorder, our patient with haploinsufficiency of *COQ4* also showed CoQ<sub>10</sub> deficiency (both CoQ<sub>10</sub> content and biosynthetic rate in cultured fibroblasts were reduced). The deficiency must have contributed to the clinical phenotype because CoQ<sub>10</sub> supplementation resulted in a stable improvement of the clinical picture, and of the growth phenotype in cells. Moreover, when CoQ<sub>10</sub> dosage was temporarily reduced to less than 1/10th of the effective dose, muscle symptoms reappeared.

In our patient, CoQ<sub>10</sub> deficiency was milder than in other patients harbouring recessive mutations,<sup>10</sup> consistent with the fact that one functional *COQ4* allele was still present. Nevertheless, it has been shown that even partial CoQ deficiency in fibroblasts (in the range of 30–50% of controls) is accompanied by increased reactive oxygen species production and cell death.<sup>10</sup>

Knockdown of *COQ4* in HeLa cells also resulted in a similar reduction of cellular CoQ<sub>10</sub>, with a direct relationship between *COQ4* mRNA levels and cellular CoQ<sub>10</sub> content. This situation appears to be unique for *COQ4* because heterozygosity for mutations in other *COQ* genes such as *PDSS2* in humans (this report) and mice,<sup>11</sup> or *COQ7* in mice,<sup>12</sup> does not cause CoQ deficiency. Taken together, these data provide further support to the notion that *COQ4* has a critical function within the CoQ<sub>10</sub> biosynthetic complex.

Haploinsufficiency of *COQ4* in the wt/ $\Delta$ *coq4* diploid yeast strain was associated with a similar defect of CoQ<sub>6</sub> content and of the enzymatic activity of complex II+III, which could be corrected by expression of wild-type *COQ4*. Heterozygous deletion of other *COQ* genes such as *COQ2* or *COQ6* had no biochemical effect, thus confirming that *COQ4* is a limiting factor in the CoQ biosynthetic process also in yeast.

Deutschbauer *et al.*,<sup>13</sup> in a large-scale screening for genes displaying haploinsufficiency in yeast found that haploinsufficiency of *COQ6* (but not of *COQ4*) resulted in a mild reduction of fitness. However, their results are not comparable with ours because they examined yeast growth in a medium containing glucose (YPD) that represses RC genes, while we performed our experiments in YPG, which forces the cells to rely on mitochondrial respiration and therefore stimulates the expression of RC genes. Another study showed that in yeast haploinsufficient genes are overrepresented in chromosome III,<sup>14</sup> but *COQ4* maps to *S cerevisiae* chromosome IV.

The clinical presentation in our patient was different from the phenotypes described in patients with mutations in other *COQ* genes (nephrotic syndrome, progressive multisystem disorder or juvenile-onset cerebellar ataxia) and more reminiscent of the two original patients with encephalomyopathy reported by Ogasahara *et al.*<sup>15</sup> in 1989. However, in our patient the phenotype was more complex as haploinsufficiency of *COQ4* was associated with the deletion of at least 80 other contiguous genes in the region (see the supplementary table, available online only, for a list of the genes present in the deleted fragment). It is also possible that these associated defects might have increased the susceptibility of our patient to the effects of a relatively mild degree of CoQ<sub>10</sub> deficiency. Other patients with CoQ deficiency and a predominantly myopathic phenotype include those reported by Sobreira *et al.*,<sup>16</sup> Di Giovanni *et al.*,<sup>17</sup> and Lalani *et al.*,<sup>18</sup> (who, however, still lack a precise genetic diagnosis) and the series of patients reported by Gempel *et al.*,<sup>19</sup> in whom CoQ deficiency was secondary to mutations in the electron transfer flavoprotein dehydrogenase gene. All these patients also benefited from CoQ<sub>10</sub> supplementation, underscoring once again the importance of a prompt diagnosis of this condition.

To our knowledge, this is the first reported patient with CoQ deficiency treated with ubiquinol, the reduced form of CoQ that has become commercially available only recently, and that has a better bioavailability than the commonly used oxidised form (ubiquinone).<sup>20</sup> Even though the dosage of CoQ<sub>10</sub> is still administered empirically, the better bioavailability of the reduced form should allow physicians to employ lower doses of the compound (in fact 15 mg/kg per day of ubiquinol was sufficient to control symptoms), allowing a better compliance with treatment especially in children. Further research is clearly needed to compare the efficacy of ubiquinol versus ubiquinone in larger series of patients with CoQ deficiency, in order to optimise treatment protocols for this disease.

In conclusion, *COQ4* should be considered a candidate gene in patients with CoQ<sub>10</sub> deficiency and encephalomyopathy. Conversely, patients with genomic rearrangements of the 9q34 region involving *COQ4* should be screened for CoQ<sub>10</sub> deficiency, because supplementation could provide some benefit to their symptoms.

## Acknowledgments


**Funding** This work was supported by Telethon Italy grant no GGP09207, CARIPARO foundation, the Spanish Ministerio de Sanidad (FIS) grant no PI 08/0500, University of Padova grant no 2010-CPDA102953, Italian Ministry of Health grant no GR-2009-1578914, National Institute of Health grant nos 1R01HD057543-01 and HD 32062, and Cariplo Foundation grant no 2007.5197.

## References

1. Trevisson E, DiMauro S, Navas P, Salviati L. Coenzyme Q deficiency in muscle. *Curr Opin Neurol*. 2011; 24:449–56. [PubMed: 21844807]
2. Marbois B, Gin P, Gulmezian M, Clarke CF. The yeast Coq4 polypeptide organizes a mitochondrial protein complex essential for coenzyme Q biosynthesis. *Biochim Biophys Acta*. 2009; 1791:69–75. [PubMed: 19022396]
3. Casarin A, Jimenez-Ortega JC, Trevisson E, Pertegato V, Doimo M, Ferrero-Gomez ML, Abbadi S, Artuch R, Quinzii C, Hirano M, Basso G, Ocana CS, Navas P, Salviati L. Functional characterization of human COQ4, a gene required for coenzyme Q10 biosynthesis. *Biochem Biophys Res Commun*. 2008; 372:35–9. [PubMed: 18474229]
4. Lopez LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, DiMauro S, Hirano M. Leigh syndrome with nephropathy and CoQ<sub>10</sub> deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. *Am J Hum Genet*. 2006; 79:1125–9. [PubMed: 17186472]
5. Spinazzi M, Casarin A, Pertegato V, Ermani M, Salviati L, Angelini C. Optimization of respiratory chain enzymatic assays in muscle for the diagnosis of mitochondrial disorders. *Mitochondrion*. 2011; 11:893–904. [PubMed: 21855655]
6. Lopez-Martin JM, Salviati L, Trevisson E, Montini G, DiMauro S, Quinzii C, Hirano M, Rodriguez-Hernandez A, Cordero MD, Sanchez-Alcazar JA, Santos-Ocana C, Navas P. Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. *Hum Mol Genet*. 2007; 16:1091–7. [PubMed: 17374725]
7. Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, Xie LX, Salviati L, Hurd TW, Vega-Warner V, Killen PD, Raphael Y, Ashraf S, Ovunc B, Schoeb DS, McLaughlin HM, Airik R, Vlangos CN, Gbadegesin R, Hinkes B, Saisawat P, Trevisson E, Doimo M, Casarin A, Pertegato V, Giorgi G, Prokisch H, Rotig A, Nurnberg G, Becker C, Wang S, Ozaltin F, Topaloglu R, Bakaloglu A, Bakaloglu SA, Muller D, Beissert A, Mir S, Berdeli A, Varpizen S, Zenker M, Matejas V, Santos-Ocana C, Navas P, Kusakabe T, Kispert A, Akman S, Soliman NA, Krick S, Mundel P, Reiser J, Nurnberg P, Clarke CF, Wiggins RC, Faul C, Hildebrandt F. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *J Clin Invest*. 2011; 121:2013–24. [PubMed: 21540551]
8. Trevisson E, Burlina A, Doimo M, Pertegato V, Casarin A, Cesaro L, Navas P, Basso G, Sartori G, Salviati L. Functional complementation in yeast allows molecular characterization of missense argininosuccinate lyase mutations. *J Biol Chem*. 2009; 284:28926–34. [PubMed: 19703900]
9. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. *N Engl J Med*. 2008; 358:2849–50. [PubMed: 18579827]
10. Quinzii CM, Lopez LC, Gilkerson RW, Dorado B, Coku J, Naini AB, Lagier-Tourenne C, Schuelke M, Salviati L, Carozzo R, Santorelli F, Rahman S, Tazir M, Koenig M, DiMauro S, Hirano M. Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ<sub>10</sub> deficiency. *FASEB J*. 2010; 24:3733–43. [PubMed: 20495179]
11. Lapointe J, Hekimi S. Early mitochondrial dysfunction in long-lived Mcl1<sup>+/-</sup> mice. *J Biol Chem*. 2008; 283:26217–27. [PubMed: 18635541]




12. Peng M, Falk MJ, Haase VH, King R, Polyak E, Selak M, Yudkoff M, Hancock WW, Meade R, Saiki R, Lunceford AL, Clarke CF, Gasser DL. Primary coenzyme Q deficiency in Pdss2 mutant mice causes isolated renal disease. *PLoS Genet.* 2008; 4:e1000061. [PubMed: 18437205]
13. Deutschbauer AM, Jaramillo DF, Proctor M, Kumm J, Hillenmeyer ME, Davis RW, Nislow C, Giaever G. Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast. *Genetics.* 2005; 169:1915–25. [PubMed: 15716499]
14. de Clare M, Pir P, Oliver SG. Haploinsufficiency and the sex chromosomes from yeasts to humans. *BMC Biol.* 2011; 9:15. [PubMed: 21356089]
15. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. *Proc Natl Acad Sci U S A.* 1989; 86:2379–82. [PubMed: 2928337]
16. Sobreira C, Hirano M, Shanske S, Keller RK, Haller RG, Davidson E, Santorelli FM, Miranda AF, Bonilla E, Mojon DS, Barreira AA, King MP, DiMauro S. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. *Neurology.* 1997; 48:1238–43. [PubMed: 9153450]
17. Di Giovanni S, Mirabella M, Spinazzola A, Crociani P, Silvestri G, Broccolini A, Tonali P, Di Mauro S, Servidei S. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ<sub>10</sub> deficiency. *Neurology.* 2001; 57:515–18. [PubMed: 11502923]
18. Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. *Arch Neurol.* 2005; 62:317–20. [PubMed: 15710863]
19. Gempel K, Topaloglu H, Talim B, Schneiderat P, Schoser BG, Hans VH, Palmafya B, Kale G, Tokatli A, Quinzii C, Hirano M, Naini A, DiMauro S, Prokisch H, Lochmuller H, Horvath R. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETF<sub>DH</sub>) gene. *Brain.* 2007; 130:2037–44. [PubMed: 17412732]
20. Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. *Biofactors.* 2008; 32:119–28. [PubMed: 19096107]



**Figure 1.** (A) Array comparative genomic hybridisation (Agilent 44 K chip) of PT 1 showing the 3.9 Mb deletion: profile of chromosome 9 showing a series of spots having an about  $-1 \log_2$  ratio at 9q34.11-q34.13. (B) Enlargement of the deleted region ranging from 129 531 to 133 523 Mb (assembly hg18). Oligos at 129 481 and 133 575 Mb resulted in normal  $\log_2$  ratio. The quality of the experiment has been considered excellent on the bases of QC metric parameters (DNA analytics). The arrow indicates the position of the *COQ4* gene within the deleted region. (C) *COQ4* copy number in genomic DNA of cultured skin fibroblasts of the patient determined by real-time quantitative PCR.





**Figure 2.** (A) *COQ4* mRNA expression and (B) respiratory chain enzyme activities, in PT1 cultured skin fibroblasts. (C) Coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) content in PT1 cells and in cells of PT2 and PT3 who harbour heterozygous mutations in *COQ1-PDSS2*. (D) CoQ<sub>10</sub> biosynthetic rate in PT1 cells measured by incorporation of <sup>14</sup>C labelled *p*-HB. (E) Growth profile of PT1 skin fibroblasts. Incubation with 10 μM CoQ<sub>10</sub> restores normal growth in patient cells. (F) Effect of CoQ<sub>10</sub> supplementation on complex II+III activity in patient cells. (G) *COQ4* mRNA levels and (H) CoQ<sub>10</sub> levels in cells stably expressing an anti-*COQ4* shRNA. (I) CoQ<sub>6</sub> content in diploid yeast strains harbouring a heterozygous deletion of *COQ4*. Transformation with a plasmid-expressing *COQ4* restores normal CoQ<sub>6</sub> content in these cells. (J) Complex II+III activity in diploid yeast strains harbouring heterozygous deletions of *COQ4*, *COQ2* and *COQ6*. Activities of other RC enzymes were normal (note that yeast does not have complex I). \*Significant versus controls; †Significant versus untreated cells.